Recombinant Anti-PD-1 & Anti-CTLA-4 Bispecific Antibody (Fab₂) is composed of the Fab of the anti-PD-1 monoclonal antibody and Fab of an antibody specific for CTLA-4. A linker is added between the two Fab. The bispecific antibody is somewhat smaller than a whole IgG, and therefore it can be cleared from the blood naturally at a faster rate. The BsAb, using a combination immunotherapy, can treat hyperproliferative disease, such as cancer and alter adverse events related to treatment with such antibodies individually. It was designed for the treatment of immunological rejective reaction.

Specifications

Target

Target 1
PD-1

Gene ID
5133

UniProt ID
Q15116

Alternative Names
PDCD1; programmed cell death 1; PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; programmed cell death protein 1; protein PD-1; systemic lupus erythematosus susceptibility 2

Target 2
CTLA-4

Gene ID
1493

UniProt ID
P16410

Alternative Names
CTLA4; cytotoxic T-lymphocyte-associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Downloads

Customer Reviews and Q&As